Article ID Journal Published Year Pages File Type
8280031 Journal of the Neurological Sciences 2012 6 Pages PDF
Abstract
The first results of the ASCOMALVA trial suggest that association of choline alphoscerate to the standard treatment with a ChE-I may represent an option to prolong beneficial effects of cholinergic therapies in AD with concomitant ischemic cerebrovascular injury.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Ageing
Preview
The ASCOMALVA trial: Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: Interim results
Authors
, , , , ,